Bromocriptine as a Potential Glucose-Lowering Agent for the Treatment of Prolactinoma With Type 2 Diabetes

Internal Medicine - Japan
doi 10.2169/internalmedicine.2755-19
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Japanese Society of Internal Medicine

Related search

Blood Glucose-Lowering Therapy in Adults With Type 2 Diabetes

Nurse Prescribing
2016English

Effects of Intensive Glucose Lowering in Type 2 Diabetes

Yearbook of Endocrinology
2009English

Impact of Cancer on Use of Glucose-Lowering Drug Treatment in Individuals With Diabetes: Potential Mechanisms

Diabetologia
Internal MedicineEndocrinologyMetabolismDiabetes
2015English

Seasonal Variation in Severe Glucose-Lowering Drug-Induced Hypoglycemia in Patients With Type 2 Diabetes

Internal Medicine
Internal MedicineMedicine
2019English

Glucose-Lowering Effect of Whey Protein Depends Upon Clinical Characteristics of Patients With Type 2 Diabetes

BMJ Open Diabetes Research and Care
EndocrinologyMetabolismDiabetes
2017English

Glucose-Lowering Therapies for Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: State-Of-The-Art Review

Mayo Clinic Proceedings
Medicine
2018English

The Potential Role of Sodium Glucose Co-Transporter 2 Inhibitors in the Early Treatment of Type 2 Diabetes Mellitus

International Journal of Clinical Practice
Medicine
2015English

Potential of Liraglutide in the Treatment of Patients With Type 2 Diabetes

Vascular Health and Risk Management
2009English

Clinical Potential of Treatment With Semaglutide in Type 2 Diabetes Patients

Drugs in Context
Molecular MedicinePharmacology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy